StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Farxiga / Forxiga (dapagliflozin) by Quarter

Farxiga / Forxiga (dapagliflozin) — Emerging Markets YoY actual (%) (%)

QuarterlyAnnual

AstraZeneca Farxiga / Forxiga (dapagliflozin): -19.0% in Q2 2026, down 32.0 pts from a year earlier. That is the lowest of the 23 quarters on record here.

Latest, Q2 2026
-19.0%
Period ended Jun 30, 2026
Change on a year earlier
-32.0 pts
13.0% in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Farxiga | | 1,804 | | ( 16 ) | | ( 19 ) | | 219 | | ( 48 ) | | 694 | | ( 19 ) | | ( 24 ) | | 808 | | 6 | | 1 | | 83 | | ( 22 ) | | ( 19 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFarxiga / Forxiga (dapagliflozin) — Emerging Markets YoY actual (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-19.0%-32.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20266.0%-16.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202512.0%0.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202519.0%-11.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202513.0%-19.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202522.0%-21.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202412.0%-15.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202430.0%-11.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202432.0%-4.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202443.0%+16.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202327.0%-12.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202341.0%+13.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202336.0%-6.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202327.0%-23.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202239.0%-22.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202228.0%-48.0 ptsForm 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-farxiga-em-act-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.